10 results on '"Kapeller, R"'
Search Results
2. Crystal structure of TYK2 kinase domain in complex with compound 16
- Author
-
Toms, A.V., primary, Leit, S., additional, Greenwood, J.R., additional, Mondal, S., additional, Carriero, S., additional, Dahlgren, M., additional, Harriman, G.C., additional, Kennedy-Smith, J.J., additional, Kapeller, R., additional, Lawson, J.P., additional, Romero, D.L., additional, Shelley, M., additional, Wester, R.T., additional, Westlin, W., additional, Mc Elwee, J.J., additional, Miao, W., additional, Edmondson, S.D., additional, and Massee, C.E., additional
- Published
- 2022
- Full Text
- View/download PDF
3. Crystal structure of TYK2 kinase domain in complex with compound 25
- Author
-
Toms, A.V., primary, Leit, S., additional, Greenwood, J.R., additional, Mondal, S., additional, Carriero, S., additional, Dahlgren, M., additional, Harriman, G.C., additional, Kennedy-Smith, J.J., additional, Kapeller, R., additional, Lawson, J.P., additional, Romero, D.L., additional, Shelley, M., additional, Wester, R.T., additional, Westlin, W., additional, Mc Elwee, J.J., additional, Miao, W., additional, Edmondson, S.D., additional, and Massee, C.E., additional
- Published
- 2022
- Full Text
- View/download PDF
4. Crystal structure of JAK3 kinase domain in complex with compound 25
- Author
-
Toms, A.V., primary, Leit, S., additional, Greenwood, J.R., additional, Mondal, S., additional, Carriero, S., additional, Dahlgren, M., additional, Harriman, G.C., additional, Kennedy-Smith, J.J., additional, Kapeller, R., additional, Lawson, J.P., additional, Romero, D.L., additional, Shelley, M., additional, Wester, R.T., additional, Westlin, W., additional, Mc Elwee, J.J., additional, Miao, W., additional, Edmondson, S.D., additional, and Massee, C.E., additional
- Published
- 2022
- Full Text
- View/download PDF
5. Crystal structure of TYK2 kinase domain in complex with compound 30
- Author
-
Toms, A.V., primary, Leit, S., additional, Greenwood, J.R., additional, Mondal, S., additional, Carriero, S., additional, Dahlgren, M., additional, Harriman, G.C., additional, Kennedy-Smith, J.J., additional, Kapeller, R., additional, Lawson, J.P., additional, Romero, D.L., additional, Shelley, M., additional, Wester, R.T., additional, Westlin, W., additional, Mc Elwee, J.J., additional, Miao, W., additional, Edmondson, S.D., additional, and Massee, C.E., additional
- Published
- 2022
- Full Text
- View/download PDF
6. Subcellular location of L1 retrotransposon-encoded ORF1p, reverse transcription products, and DNA sensors in lupus granulocytes.
- Author
-
Moadab F, Sohrabi S, Wang X, Najjar R, Wolters JC, Jiang H, Miao W, Romero D, Zaller DM, Tran M, Bays A, Taylor MS, Kapeller R, LaCava J, and Mustelin T
- Abstract
Background: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with an unpredictable course of recurrent exacerbations alternating with more stable disease. SLE is characterized by broad immune activation and autoantibodies against double-stranded DNA and numerous proteins that exist in cells as aggregates with nucleic acids, such as Ro60, MOV10, and the L1 retrotransposon-encoded ORF1p., Results: Here we report that these 3 proteins are co-expressed and co-localized in a subset of SLE granulocytes and are concentrated in cytosolic dots that also contain DNA: RNA heteroduplexes and the DNA sensor ZBP1, but not cGAS. The DNA: RNA heteroduplexes vanished from the neutrophils when they were treated with a selective inhibitor of the L1 reverse transcriptase. We also report that ORF1p granules escape neutrophils during the extrusion of neutrophil extracellular traps (NETs) and, to a lesser degree, from neutrophils dying by pyroptosis, but not apoptosis., Conclusions: These results bring new insights into the composition of ORF1p granules in SLE neutrophils and may explain, in part, why proteins in these granules become targeted by autoantibodies in this disease., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
7. Structures, functions and adaptations of the human LINE-1 ORF2 protein.
- Author
-
Baldwin ET, van Eeuwen T, Hoyos D, Zalevsky A, Tchesnokov EP, Sánchez R, Miller BD, Di Stefano LH, Ruiz FX, Hancock M, Işik E, Mendez-Dorantes C, Walpole T, Nichols C, Wan P, Riento K, Halls-Kass R, Augustin M, Lammens A, Jestel A, Upla P, Xibinaku K, Congreve S, Hennink M, Rogala KB, Schneider AM, Fairman JE, Christensen SM, Desrosiers B, Bisacchi GS, Saunders OL, Hafeez N, Miao W, Kapeller R, Zaller DM, Sali A, Weichenrieder O, Burns KH, Götte M, Rout MP, Arnold E, Greenbaum BD, Romero DL, LaCava J, and Taylor MS
- Subjects
- Humans, Cryoelectron Microscopy, RNA genetics, Crystallography, X-Ray, DNA biosynthesis, DNA genetics, Immunity, Innate, Interferons biosynthesis, Endonucleases chemistry, Endonucleases genetics, Endonucleases metabolism, Long Interspersed Nucleotide Elements genetics, RNA-Directed DNA Polymerase chemistry, RNA-Directed DNA Polymerase genetics, RNA-Directed DNA Polymerase metabolism, Reverse Transcription
- Abstract
The LINE-1 (L1) retrotransposon is an ancient genetic parasite that has written around one-third of the human genome through a 'copy and paste' mechanism catalysed by its multifunctional enzyme, open reading frame 2 protein (ORF2p)
1 . ORF2p reverse transcriptase (RT) and endonuclease activities have been implicated in the pathophysiology of cancer2,3 , autoimmunity4,5 and ageing6,7 , making ORF2p a potential therapeutic target. However, a lack of structural and mechanistic knowledge has hampered efforts to rationally exploit it. We report structures of the human ORF2p 'core' (residues 238-1061, including the RT domain) by X-ray crystallography and cryo-electron microscopy in several conformational states. Our analyses identified two previously undescribed folded domains, extensive contacts to RNA templates and associated adaptations that contribute to unique aspects of the L1 replication cycle. Computed integrative structural models of full-length ORF2p show a dynamic closed-ring conformation that appears to open during retrotransposition. We characterize ORF2p RT inhibition and reveal its underlying structural basis. Imaging and biochemistry show that non-canonical cytosolic ORF2p RT activity can produce RNA:DNA hybrids, activating innate immune signalling through cGAS/STING and resulting in interferon production6-8 . In contrast to retroviral RTs, L1 RT is efficiently primed by short RNAs and hairpins, which probably explains cytosolic priming. Other biochemical activities including processivity, DNA-directed polymerization, non-templated base addition and template switching together allow us to propose a revised L1 insertion model. Finally, our evolutionary analysis demonstrates structural conservation between ORF2p and other RNA- and DNA-dependent polymerases. We therefore provide key mechanistic insights into L1 polymerization and insertion, shed light on the evolutionary history of L1 and enable rational drug development targeting L1., (© 2023. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF
8. Regional economic costs of climate change: An interdisciplinary impact assessment for Upper Austria.
- Author
-
Goers S, Kapeller R, Schneider F, Dirschmid D, and Ludwig R
- Subjects
- Austria, Forestry, Geography, Climate Change, Agriculture
- Abstract
Region-specific meteorological data show that Upper Austria will mainly be affected by increasing temperatures (up to +2.7 °C in 2050) and decreasing precipitation (up to - 27 mm in 2050). Using an interdisciplinary framework, we derive climatic developments and quantify the resulting direct sectoral and macroeconomic impacts for Upper Austria. Based on a set of climate change indicators, sectoral damages are monetized for selected impact chains in forestry, health, agriculture, space heating and cooling, and winter tourism. These damage costs are used as input for ex-ante simulations to quantify the macroeconomic impacts in 2022-2050. The results show an annual decline in gross regional product, accompanied by an annual decline in employment. This study provides a basis for decision making in Upper Austria, as well as in regions with comparable geographical, economic or demographic structures, and highlights the importance of region-specific climate change adaptation strategies., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 Elsevier Ltd. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
9. Discovery of a Potent and Selective Tyrosine Kinase 2 Inhibitor: TAK-279.
- Author
-
Leit S, Greenwood J, Carriero S, Mondal S, Abel R, Ashwell M, Blanchette H, Boyles NA, Cartwright M, Collis A, Feng S, Ghanakota P, Harriman GC, Hosagrahara V, Kaila N, Kapeller R, Rafi SB, Romero DL, Tarantino PM, Timaniya J, Toms AV, Wester RT, Westlin W, Srivastava B, Miao W, Tummino P, McElwee JJ, Edmondson SD, and Masse CE
- Subjects
- Humans, TYK2 Kinase, Genome-Wide Association Study, Autoimmune Diseases drug therapy, Arthritis, Rheumatoid, Psoriasis drug therapy
- Abstract
TYK2 is a key mediator of IL12, IL23, and type I interferon signaling, and these cytokines have been implicated in the pathogenesis of multiple inflammatory and autoimmune diseases such as psoriasis, rheumatoid arthritis, lupus, and inflammatory bowel diseases. Supported by compelling data from human genome-wide association studies and clinical results, TYK2 inhibition through small molecules is an attractive therapeutic strategy to treat these diseases. Herein, we report the discovery of a series of highly selective pseudokinase (Janus homology 2, JH2) domain inhibitors of TYK2 enzymatic activity. A computationally enabled design strategy, including the use of FEP+, was instrumental in identifying a pyrazolo-pyrimidine core. We highlight the utility of computational physics-based predictions used to optimize this series of molecules to identify the development candidate 30 , a potent, exquisitely selective cellular TYK2 inhibitor that is currently in Phase 2 clinical trials for the treatment of psoriasis and psoriatic arthritis.
- Published
- 2023
- Full Text
- View/download PDF
10. Potent and selective TYK2-JH1 inhibitors highly efficacious in rodent model of psoriasis.
- Author
-
Leit S, Greenwood JR, Mondal S, Carriero S, Dahlgren M, Harriman GC, Kennedy-Smith JJ, Kapeller R, Lawson JP, Romero DL, Toms AV, Shelley M, Wester RT, Westlin W, McElwee JJ, Miao W, Edmondson SD, and Masse CE
- Subjects
- Animals, Humans, Janus Kinases, Mice, Protein Kinase Inhibitors pharmacology, Protein Kinase Inhibitors therapeutic use, Rodentia, Psoriasis drug therapy, TYK2 Kinase
- Abstract
TYK2 is a member of the JAK family of kinases and a key mediator of IL-12, IL-23, and type I interferon signaling. These cytokines have been implicated in the pathogenesis of multiple inflammatory and autoimmune diseases such as psoriasis, rheumatoid arthritis, lupus, and inflammatory bowel diseases. Supported by compelling data from human genetic association studies, TYK2 inhibition is an attractive therapeutic strategy for these diseases. Herein, we report the discovery of a series of highly selective catalytic site TYK2 inhibitors designed using FEP+ and structurally enabled design starting from a virtual screen hit. We highlight the structure-based optimization to identify a lead candidate 30, a potent cellular TYK2 inhibitor with excellent selectivity, pharmacokinetic properties, and in vivo efficacy in a mouse psoriasis model., (Copyright © 2022 Elsevier Ltd. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.